ArticleBMC research notes2022

Radiomics combined with clinical characteristics predicted the progression-free survival time in first-line targeted therapy for advanced non-small cell lung cancer with EGFR mutation.

Jian-Man Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.